January 18, 2019

Hinder Accepts Medical Science Liaison Role at Reata Pharmaceuticals

Lucy Hinder, Ph.D., served as the PNR&D team lead for diabetic neuropathy research. During her 10 years in the laboratory, she produced 19 peer-reviewed manuscripts, one book chapter and one electronic article.

Lucy Hinder, Ph.D., a research investigator for the University of Michigan Program for Neurology Research & Discovery (PNR&D), is departing U-M, Eva Feldman, Ph.D., M.D., director of PNR&D announced today (Jan. 18). Hinder is advancing her career by taking a medical science liaison role with Reata Pharmaceuticals.

“Lucy has been a truly fantastic member of our laboratory and I am incredibly proud to see her utilize her vast diabetic neuropathy knowledge in a new capacity,” said Feldman, the Russell N. DeJong Professor of Neurology. “I am very thankful for the 10 years she has spent with us, during which she made significant advancements in understanding causes and treatments of diabetic neuropathy.”

Hinder has served as the PNR&D team lead for diabetic neuropathy research. During her 10 years in the laboratory, she has produced 19 peer-reviewed manuscripts, one book chapter and one electronic article. In 2015, the American Neurological Association (ANA) awarded her the Wolfe Neuropathy Research Prize. She had a featured manuscript in the 2013 Bioscientifica Journals. Hinder has received travel awards to attend the 2013 Seahorse Bioscience Conference and the 2015 and 2017 Peripheral Nerve Society (PNS) Conferences. She has been a session co-chair, moderated and presented at numerous international conferences, including the ANA, PNS, American Diabetes Association and the Centre for Brain Research (University of Auckland).

In her role as a medical science liaison, Hinder will be responsible for interacting with clinical physicians to update and educate them about new therapies available to patients. Reata Pharmaceuticals develops novel therapeutics for patients with serious and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.

Following Hinder’s exit from PNR&D, Phillipe O’Brien, Ph.D., and Stephanie Eid, Ph.D., will take over as team leaders of diabetic neuropathy research. A research investigator, O’Brien is in his seventh year with PNR&D. Eid, a postdoctoral fellow, joined the PNR&D lab in 2017.